<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881984</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13050530</org_study_id>
    <nct_id>NCT01881984</nct_id>
  </id_info>
  <brief_title>Use of Ravicti™ in Patients With MCAD Deficiency With the 985A&gt;G (K304E) Mutation</brief_title>
  <official_title>Use of Glycerol Phenylbutyrate (Ravicti™) as a Chaperone to Stabilize Enzyme in Patients With MCAD Deficiency Due to the Common MCAD 985A&gt;G (K304E) Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Horizon Pharma Ireland, Ltd., Dublin Ireland</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a medical research study to test a medication in adult patients with a disease called
      medium-chain acyl-CoA dehydrogenase (MCAD) deficiency caused by at least one copy of the
      985A&gt;G mutation. The medication is glycerol phenylbutyrate, called Ravicti, which is
      currently FDA approved for the treatment of urea cycle disorders. Previous research suggests
      that Ravicti may also be effective in the treatment MCAD deficiency. This study will
      investigate the safety and efficacy (how well it works) of Ravicti in patients with MCAD
      deficiency caused by having at least one copy of the 985A&gt;G mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation in the study will require one overnight admission and three outpatient visits
      at the Clinical and Translational Research Center at Children's Hospital of Pittsburgh of
      UPMC (also called the PCTRC). The total length of the study is 7 weeks.

      Subjects will have blood work and an intravenous access line (IV) placed for several blood
      draws during the visit. Subjects will begin fasting at 8pm during the admission, which means
      they may consume only non-caloric fluids (water, unsweetened black coffee or tea, or
      sugar-free beverages). The next morning, fasting blood work will be obtained. The subject can
      then eat breakfast and will receive the study drug, Ravicti. The total time of fasting will
      be 12 hours.

      Dosing for this study will begin at 2 grams/m2/day, which is about one-fifth (1/5) the dose
      used for other disorders. The reason for starting the dose lower in MCAD patients is that
      Ravicti is metabolized by the MCAD enzyme. Following the initial dose, blood will be drawn
      from the IV every two hours for 8 hours. These blood studies will check the levels of Ravicti
      in the subject's blood and monitor how the subject's body metabolizes them. The subject will
      be discharged 8 hours after drug administration. Following discharge, the subject will take
      Ravicti every day for two weeks.

      Visit 2: After two weeks at a dose of 2 grams/m2/day, the subject will fast after 8 PM, and
      will come to the PCTRC the following morning to have an IV placed and blood draws. If the
      subject's blood work from the first visit shows that there is no concern, the subject's dose
      will be increased to 4 grams/m2/day. The subject will receive the first dose at this level in
      the PCTRC with breakfast, and blood samples will be collected from the IV every 2 hours for
      the next 8 hours. The subject will continue on this dose for two weeks.

      Visit 3: After two weeks at a dose of 4 grams/m2/day, the subject will fast after 8 PM, and
      will come to the PCTRC the following morning to have an IV placed and blood draws. If the
      subject's blood work from the previous visit shows that there is no concern, the subject's
      dose will be increased to 6 grams/m2/day. The subject will receive the first dose at this
      level in the PCTRC with breakfast, and blood samples will be collected from the IV every 2
      hours for the next 8 hours. The subject will continue on this dose for two weeks.

      Visit 4 (final): After two weeks at a dose of 6 grams/m2/day, the subject will fast after 8
      PM, and will come to the CTRC the following morning to have one blood draw. The subject will
      return any unused Ravicti, and their study participation will be completed.

      All study procedures will be done at no cost to the subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic Stress</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes in the assessments of metabolic stress pre- and post-dosing with Ravicti will be the main outcome variable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (pK)Analysis</measure>
    <time_frame>7 weeks</time_frame>
    <description>Results from the pharmacokinetic (pK)analysis (the rate of conversion of the phenylbutyrate to phenylacetate) will also be reviewed to assess for changes pre- and post-dosing with Ravicti as well as changes in these levels at the different doses of Ravicti.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency</condition>
  <arm_group>
    <arm_group_label>Ravicti</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravicti</intervention_name>
    <description>Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day</description>
    <arm_group_label>Ravicti</arm_group_label>
    <other_name>glycerol phenylbutyrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmation of a diagnosis of MCAD deficiency

          -  at least one copy of 985A&gt;G MCAD mutation

          -  ability to follow protocol

        Exclusion Criteria:

          -  positive pregnancy test

          -  currently breastfeeding

          -  currently taking any medication for which there is a potential drug interaction with
             Ravicti, includes corticosteroids, valproic acid, haloperidol, and probenecid

          -  liver or kidney insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Vockley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh/Children's Hospital of Pittsburgh of UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/medium-chain-acyl-coa-dehydrogenase-deficiency</url>
    <description>U.S. National Library of Medicine Genetics Home Reference Information on MCAD Deficiency</description>
  </link>
  <reference>
    <citation>Kormanik K, Kang H, Cuebas D, Vockley J, Mohsen AW. Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. Mol Genet Metab. 2012 Dec;107(4):684-9. doi: 10.1016/j.ymgme.2012.10.009. Epub 2012 Oct 18.</citation>
    <PMID>23141465</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>April 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2017</results_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Gerard Vockley, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Pediatrics/Human Genetics</investigator_title>
  </responsible_party>
  <keyword>Medium-chain acyl-CoA dehydrogenase deficiency</keyword>
  <keyword>MCAD deficiency</keyword>
  <keyword>MCADD</keyword>
  <keyword>ACADM deficiency</keyword>
  <keyword>MCADH deficiency</keyword>
  <keyword>985A&gt;G mutation</keyword>
  <keyword>K304E mutation</keyword>
  <keyword>Ravicti</keyword>
  <keyword>glycerol phenylbutyrate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ravicti</title>
          <description>Open Label Study
Ravicti: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ravicti</title>
          <description>Open Label Study
Ravicti: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Stress</title>
        <description>Changes in the assessments of metabolic stress pre- and post-dosing with Ravicti will be the main outcome variable.</description>
        <time_frame>7 weeks</time_frame>
        <population>Due to the small sample size in this Phase I study, details on the analysis cannot be provided due to concerns with subject confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Ravicti</title>
            <description>Open Label Study
Ravicti: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Stress</title>
          <description>Changes in the assessments of metabolic stress pre- and post-dosing with Ravicti will be the main outcome variable.</description>
          <population>Due to the small sample size in this Phase I study, details on the analysis cannot be provided due to concerns with subject confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (pK)Analysis</title>
        <description>Results from the pharmacokinetic (pK)analysis (the rate of conversion of the phenylbutyrate to phenylacetate) will also be reviewed to assess for changes pre- and post-dosing with Ravicti as well as changes in these levels at the different doses of Ravicti.</description>
        <time_frame>7 weeks</time_frame>
        <population>Due to the small sample size in this Phase I study, details on the analysis cannot be provided due to concerns with subject confidentiality.</population>
        <group_list>
          <group group_id="O1">
            <title>Ravicti</title>
            <description>Open Label Study
Ravicti: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (pK)Analysis</title>
          <description>Results from the pharmacokinetic (pK)analysis (the rate of conversion of the phenylbutyrate to phenylacetate) will also be reviewed to assess for changes pre- and post-dosing with Ravicti as well as changes in these levels at the different doses of Ravicti.</description>
          <population>Due to the small sample size in this Phase I study, details on the analysis cannot be provided due to concerns with subject confidentiality.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 7 weeks</time_frame>
      <desc>The definition of adverse event and a serious adverse event used to collect this information did not differ from the clinicaltrials.gov definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ravicti</title>
          <description>Open Label Study
Ravicti: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated PBA level</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased reflexes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The purpose of this phase 1 trial was to establish a safe dose for treatment of patients with MCAD deficiency due to the common mutations, and to evaluate biomarkers of fatty acid metabolism in treated patients vs their pretreatment values.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Gerard Vockley</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-692-7746</phone>
      <email>gerard.vockley@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

